TIDMGNS
RNS Number : 9331R
Genus PLC
01 November 2023
For Immediate Release
1 November 2023
Genus plc
("Genus", the "Group" or the "Company")
Capital Markets Event - Delivering the PRRS Resistant Pig
("PRP")
Genus plc (LSE:GNS), a leading global animal genetics company,
is hosting a Capital Markets Event ("CME") today at 10.00am in
London for institutional investors and sell-side analysts.
Chief Executive Officer, Jorgen Kokke, and Chief Financial
Officer, Alison Henriksen, will be joined by senior leaders from
the Group's porcine division, Pig Improvement Company ("PIC"), to
take a deep dive into the Group's pioneering PRRS* Resistant Pig
("PRP") programme and the path to commercialisation.
PRRS is the most economically significant disease affecting US
pork production (1) . Symptoms of PRRS include fever, respiratory
distress, premature births and increased post wean mortality. Genus
has demonstrated that its PRP is resistant to prevalent PRRS
strains (2) .
The Company is preparing for commercialisation of PRP whilst
regulatory approvals in various countries are in progress. The
Colombian government was the first to issue a positive
determination for PRP last month, and, as previously outlined,
Genus anticipates approval from the United States Food and Drug
Administration ("FDA") in the first half of 2024.
Speakers at the event will outline:
-- The strength of PIC's platform; market-leading genetics, a
well-invested global supply chain to disseminate PRP genetics to
customers, deep relationships with long-term customers underpinned
by the royalty model and a world class team
-- The technical performance of PRP genetics; how the CD163 gene
edit works, why PIC's research shows it delivers PRRS resistance,
the strong intellectual property position and how PIC breeds
homozygous edited animals
-- The impact PRRS has on the pork value chain; PRRS is an
increasingly endemic global disease affecting almost all major pork
producing regions. Research suggests that more than 60% of US sow
herds are PRRS positive at any given time(3) and that the average
cost to US pig farmers is approximately $6/pig
-- How PIC plans to disseminate PRP genetics; investments PIC
has made in the PRP supply chain ahead of commercialisation and how
dissemination to customer systems will work in practice once FDA
and other regulatory approvals have been granted
-- PIC's strategy for driving market acceptance; how PIC is
developing thoughtful and responsible messaging for all
stakeholders in the pork value chain, the research investments PIC
is making to quantitatively demonstrate the welfare and
sustainability benefits, and the industry partners PIC is working
with to communicate the shared benefits of PRP
-- The PRP regulatory timeline; progress being made with the FDA
and regulatory bodies in other countries, including those that are
important US export markets
-- The opportunity for Genus; the global market opportunity, the
potential financial performance of PRP in the US and the prospect
of compelling returns on Genus's investments
A copy of the CME presentation will be made available on the
Group's investor relations website
(https://www.genusplc.com/investors) and a recording of the event
will be published as soon as practicable after the event.
For further information please contact:
Genus plc Tel: +44 (0)1256 345 970
Jorgen Kokke, Chief Executive Officer
Alison Henriksen, Chief Financial Officer
Anand Date, Investor Relations Director
Buchanan Tel: +44 (0)207 466 5000
Charles Ryland; Chris Lane; Sophie Wills; Verity Parker
About Genus
Genus is a world-leading animal genetics company. Genus creates
advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming
and food producers. Its technology is applicable across livestock
species and is currently commercialised by Genus in the dairy, beef
and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries
under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs)
and comprise semen, embryos and breeding animals with superior
genetics to those animals currently in farms. Genus's customers'
animals produce offspring with greater production efficiency, and
quality, and use these to supply the global dairy and meat supply
chains.
The Group's competitive edge has been created from the ownership
and control of proprietary lines of breeding animals, the
biotechnology used to improve them and its global supply chain,
technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus
companies operate in over twenty-five countries on six continents,
with research laboratories located in Madison, Wisconsin, USA.
* Porcine Reproductive and Respiratory Syndrome virus
1 "Swine Disease Manual" (4(th) Edition), Edited by EJ Neumann,
A Ramirez, and KJ Schwartz, Iowa State University, College of
Veterinary Medicine;
https://vetmed.iastate.edu/vdpam/about/production-animal-medicine/swine/swine-disease-manual
2 Studies of the safety and efficacy of Genus's PRP are being
reviewed by the US Food and Drug Administration and other
regulatory agencies around the world
3 University of Minnesota, Morrison Swine Health Monitoring
Program
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRBDGSXXDGXB
(END) Dow Jones Newswires
November 01, 2023 03:00 ET (07:00 GMT)
Genus (LSE:GNS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Genus (LSE:GNS)
Historical Stock Chart
From Jul 2023 to Jul 2024